Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
Status:
Recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in
patients with metastatic castration-resistant prostate cancer who have progressed following
treatment with androgen receptor axis-targeted therapy (ARAT).